Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

A new drug for the treatment of neurogenic orthostatic hypotension (NOH) has been approved by the FDA under its accelerated approval program. Droxidopa is a prodrug to norepinephrine.

Pharmacology Update: Droxidopa Capsules (Northera™)